WO2008008819A3 - Diagnosis and treatment of neurological inflammation - Google Patents

Diagnosis and treatment of neurological inflammation Download PDF

Info

Publication number
WO2008008819A3
WO2008008819A3 PCT/US2007/073233 US2007073233W WO2008008819A3 WO 2008008819 A3 WO2008008819 A3 WO 2008008819A3 US 2007073233 W US2007073233 W US 2007073233W WO 2008008819 A3 WO2008008819 A3 WO 2008008819A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
diagnosis
neurological
inflammatory
neurological inflammation
Prior art date
Application number
PCT/US2007/073233
Other languages
French (fr)
Other versions
WO2008008819A2 (en
Inventor
Andrew K Ottens
Mark S Gold
Firas H Kobeissy
Kevin Kw Wang
Ronald L Hayes
Original Assignee
Univ Florida
Andrew K Ottens
Mark S Gold
Firas H Kobeissy
Kevin Kw Wang
Ronald L Hayes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Andrew K Ottens, Mark S Gold, Firas H Kobeissy, Kevin Kw Wang, Ronald L Hayes filed Critical Univ Florida
Publication of WO2008008819A2 publication Critical patent/WO2008008819A2/en
Publication of WO2008008819A3 publication Critical patent/WO2008008819A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Drug abuse (METH and MDMA) animals are showing a pro-inflammatory phenotype similar to that of TBI. Detection of cytokines in neurological injury is shown. Methods of treatment of neurological chemical injury include the use of an anti-inflammatory agents due to the elevation of inflammatory related cytokines.
PCT/US2007/073233 2006-07-11 2007-07-11 Diagnosis and treatment of neurological inflammation WO2008008819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81987406P 2006-07-11 2006-07-11
US60/819,874 2006-07-11

Publications (2)

Publication Number Publication Date
WO2008008819A2 WO2008008819A2 (en) 2008-01-17
WO2008008819A3 true WO2008008819A3 (en) 2008-12-11

Family

ID=38924132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073233 WO2008008819A2 (en) 2006-07-11 2007-07-11 Diagnosis and treatment of neurological inflammation

Country Status (1)

Country Link
WO (1) WO2008008819A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010262952B2 (en) * 2009-06-19 2016-01-07 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
CA3170609A1 (en) * 2013-01-03 2014-07-10 Meso Scale Technologies, Llc Assay panels for a multiplexed analysis of a set of cytokines
US20200174015A1 (en) * 2017-06-15 2020-06-04 University Of Geneva Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084880A1 (en) * 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILDEBRAND F. ET AL.: "Importance of cytokines in the posttraumatic inflammatory reaction", UNFALLCHIRURG, vol. 108, no. 10, 21 September 2005 (2005-09-21), pages 793 - 803, XP019320741 *
WANG C.C. ET AL.: "Array-based multiplexed screening and quantitation of human cytokines and chemokines", JOURNAL OF PROTEOME RESEARCH, vol. 1, no. 4, pages 337 - 343, XP002365507 *

Also Published As

Publication number Publication date
WO2008008819A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
IL197240A0 (en) Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
DE602005005589D1 (en) Quick coupling device and tractor
IL181706A0 (en) The treatment of inflammatory disorders and pain
EP1793747A4 (en) Improved ultrasound catheter devices and methods
NO20044054L (en) Administration of agents for the treatment of inflammation
EP1737428A4 (en) Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
EP1804813A4 (en) Formulations and methods for treatment of inflammatory diseases
ITMI20020078A0 (en) DEVICE USABLE IN THE TREATMENT OF RESPIRATORY TRACT DISEASES
EP1827332A4 (en) Topical nitric oxide donor devices and methods for their therapeutic use
EP1744740A4 (en) Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
IL176968A0 (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
LT2262778T (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
ZA200609974B (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
CY2018006I1 (en) THERAPEUTIC FORMULATION OF CLADRIVINE FOR THE THERAPEUTIC TREATMENT OF PLAQUE STICHERONE
IL200549A0 (en) 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
EP1724271A4 (en) Preventive and/or therapeutic agent for neutrophilic inflammation disease
WO2009024667A3 (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
WO2008008819A3 (en) Diagnosis and treatment of neurological inflammation
IS7444A (en) Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases
NO20070892L (en) Compositions of N-glycolylneuraminic acid and their use in the treatment of colds.
DK1670482T4 (en) USE OF CICLESONIDE IN THE TREATMENT OF RESPIRATORY DISEASES
IT1390833B1 (en) METHOD AND DEVICE FOR THE TREATMENT OF BALL HUBS FOR HOMOCINETIC JOINTS
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
IL179040A0 (en) Methods of using and compositions comrpising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
WO2006117624A3 (en) Kynurenic acid and salts thereof for the prevention and treatment of shock

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812796

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07812796

Country of ref document: EP

Kind code of ref document: A2